$TRU

UBS Adjusts Price Target on TransUnion to $83 From $75, Maintains Neutral Rating

UBS raised its price target for TransUnion from $75 to $83 while maintaining a neutral rating. The stock is currently trading at $79.02, up 1.00% on the day and 18.49% year-to-date, but down 7.50% over five days. The adjustment is based on a weighted average of various composite ratings, including valuation, EPS revisions, and visibility.

Original reporting
Published Oct 21, 2026, 1:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 2:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$TRU
Neutral
medium confidence
Mentioned
$TRU
Relevance
5/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$TRUNeutralLow
01

Why it matters

The target increase reflects UBS's revised earnings expectations but maintains a neutral stance, indicating modest upside.

02

Market read

Analyst target revisions can influence short‑term trading activity, though the neutral rating limits broader market moves.

03

What to watch

Potential competitive pressures in credit reporting could temper the impact of the target raise.

Relevance 5/10Novelty 5/10Timing: pre‑market today

Background

UBS issued a composite rating update, adjusting valuation assumptions for TransUnion.

Company-level read

Ticker impact

$TRUNeutralMedium confidence
Context

UBS raised its price target on TransUnion to $83 from $75 and kept a neutral rating.

Expected impact

slight upward pressure as investors price in the higher target

Evidence & confidence

Target raise signals improved valuation expectations but no rating upgrade, limiting upside.

Market effects

May slightly lift the consumer data services sector as analysts see better prospects.

Limited to US equity markets where TransUnion trades.

Minimal global impact.

Counterpoint

The neutral rating suggests limited upside despite the higher target; price may remain flat.

Key entities

  • TransUnion

    US‑listed consumer credit reporting firm (ticker TRU).

  • UBS

    Global investment bank providing the price target revision.

Related articles

$TRUHighAI 8/10

TransUnion (TRU) (Q3 2026) Earnings Call Highlights: Revenue and EPS Beat Guidance

TransUnion (TRU) reported Q3 2026 earnings beating guidance with 8% revenue growth and 14% EPS growth. International business grew 10%, led by India and Latin America. The company reduced its leverage ratio and increased share repurchase authorization. However, rising interest rates are expected to slow mortgage volumes and auto affordability, leading to a sequential deceleration in revenue growth to 3-6% in Q4. Legal and regulatory expenses also contributed to margin contraction.

$TRUHighAI 8/10

TransUnion (TRU) Q3 2026 Earnings Call Transcript

TransUnion (TRU) reported Q3 2026 organic revenue growth of 8%, with adjusted EPS up 14%. U.S. Markets revenue rose 7%, while international revenue grew 10%, led by India and Latin America. The company repurchased $126M in shares and raised its repurchase authorization by $1B. Despite economic uncertainties, TRU raised its full-year guidance, expecting 8-9% revenue growth and 12-13% adjusted EPS growth.

$TRUMed

TransUnion Q3 2026 Earnings Call Summary

TransUnion reported Q3 2026 earnings, highlighting 18% growth in India and Latin America, 13% auto growth, and 10% international growth. The company expects full-year share repurchases of $500M and plans to expand its OneTru platform globally. Management noted resilience in US Financial Services despite inflation and higher interest rates, and provided guidance for Q4, including potential impacts from regulatory changes and market softening.

$TRUHighAI 8/10

TransUnion Q3 2026 slides: insurance drives growth amid margin pressure

TransUnion (TRU) reported Q3 2026 earnings with revenue of $1.31B, matching estimates, and EPS of $1.25, beating forecasts. Revenue grew 8% organically, driven by insurance and international markets. However, adjusted EBITDA margin contracted by 90 basis points to 35.4%. The company raised full-year guidance, expecting 8-9% revenue growth and 12-13% EPS growth. Shares fell 2.19% in premarket trading.